Phio Pharmaceuticals Corp. current report, 07 October 2016

Full document

Business Context and Reporting Period

This Form 8-K was filed by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) on October 7, 2016. The report discloses a significant corporate development involving an exclusive option agreement entered into on the same date.

Key Financial Metrics

The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a potential acquisition.

Material Changes

The primary material event is the execution of an exclusive option agreement to acquire all outstanding capital stock of MirImmune, Inc. Key terms include:

  • Consideration: The Company will issue shares equal to 19.99% of its then-outstanding common stock upon exercise of the option.
  • Contingent Value: Additional consideration may be required if MirImmune reaches certain milestones.
  • Option Period: RXi Pharmaceuticals may exercise the option at any time prior to April 5, 2017.
  • Obligation: The Company has no obligation to exercise the option.

Guidance, Outlook, and Risks

Management included a Safe Harbor statement regarding forward-looking statements, noting that actual results may differ materially from expectations. Specific risks identified include:

  • The potential acquisition of MirImmune may not proceed.
  • Uncertainty regarding the actual realization of anticipated benefits from the purchase.
  • Risks related to the Company's ability to control the timing and terms of the purchase.
  • General risks detailed in the Company's most recent Annual Report on Form 10-K.

Investor Verification Checklist

  • Verify the exact number of shares constituting 19.99% of the Company's outstanding stock as of the option exercise date.
  • Review the specific milestones defined in the agreement that trigger additional consideration.
  • Assess the dilution impact on existing shareholders if the option is exercised.
  • Confirm the current status of the option (exercised, expired, or pending) in subsequent filings.